NCT04727554
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: Mesothelin+
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for part 1 of the study
Exclusions: Patients with active, unstable, untreated, or symptomatic central nervous system (brain or leptomeningeal) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT04727554